Skip Ribbon Commands
Skip to main content
Survivor Profile

Betting on Science

Diagnosed with a rare and incurable blood cancer, Jack Whelan is a passionate booster for research, clinical trials and affordable treatments. By Betty Russell
Photographs by Bryce Vickmark

Editor's Note: On Nov. 16, 2017, Cancer Today learned that Jack Whelan died. Jack was a relentless patient advocate who was also a friend to many at the American Association for Cancer Research. The editors of Cancer Today send our condolences to Jack’s family and all who are affected by this great loss. 

​Jack Whelan's face lights up when he talks about the antique phonographs displayed around his home in Andover, Mass. He enthusiastically demonstrates how turning the crank on the old machines starts the music playing, and then unexpectedly tosses a rolled-up sock into the horn of a pristine Victrola.

Jack and the Jimmy Fund: A labor of love
A survivor has a long-standing connection to a cancer center.

“There were no volume controls on the
early phonographs,” he says. “So people would say ‘put a sock in it’ when they wanted someone 
to … lower the volume.”

Trim, fit and with a full head of brown hair, Whelan says he is often mistaken for someone much younger than his 65 years, an impression confirmed by his attitude when he shares his encyclopedic knowledge of early record players. Behind his boyish enthusiasm and impish grin is a razor-sharp mind, a dogged inquisitiveness and a penchant for research. The same traits that fueled his search for antique phonographs—he has more than 200 in his collection—led to a successful career as a research analyst specializing in information technologies for large investment firms. Six years ago, his research skills and persistence were again put to the test when he was told he had cancer.

In 2007, Whelan, then 58, began to notice he couldn’t keep up his typical fast pace on daily power walks. He felt “bone tired” and started having nosebleeds. “I [had been] healthy, fit and active,” Whelan says. “The only medication I took was 81 milligrams of aspirin. When I started having symptoms, I thought it was a sign that I was getting older.”

Feeling that something wasn’t quite right, Whelan scheduled a check-up, where a routine test revealed a high blood protein level. His doctor referred him to Nancy Chun, a hematologist-oncologist at Winchester Hospital in a nearby Massachusetts suburb. Chun ordered a host of tests, including a chest X-ray, PET scan, CT scan, complete blood chemistry workup, and bone marrow biopsy. When the results were in, her diagnosis was Waldenström macroglobulinemia, a rare and incurable blood cancer.
Jack Whelan relies on strong family support in facing his cancer. Top, Whelan and his wife, Jan, show their twin granddaughters, Catherine and Madeleine Gorecki, an antique phonograph from Whelan's extensive collection. Above, his family, including his youngest daughter, Karen Hakenson, gathers around the kitchen table.​
 “I honestly wasn’t scared until I received the actual diagnosis,” Whelan says. “My wife and daughters started researching it on the web as well. We were worried that it was incurable and had a poor survival rate. But I was always confident that we’d find a way to extend my life.”

Waldenström is a type of non-Hodgkin lymphoma that starts in certain white blood cells, called B lymphocytes. The cancerous cells, which are located mainly in the bone marrow, produce abnormally large amounts of a protein called immunoglobulin M (IgM) that causes the blood to thicken, a condition called hyperviscosity. Common symptoms include nosebleeds, headaches, weakness, fever, loss of appetite and neuropathy.

Chun had never treated a patient with Waldenström—only 1,000 to 1,500 people are diagnosed with it each year in the United States—so Whelan asked for a referral to a doctor at the Dana-Farber Cancer Institute in Boston. Chun sent him 
to Irene Ghobrial, a hematologist-oncologist there. Ghobrial advised the Whelans that, although his type of cancer couldn’t be cured, it was slow-growing. She also told them that the survival information they found online didn’t necessarily apply to patients like Whelan, who was younger than most Waldenström patients, otherwise healthy and in a lower risk group. (Waldenström is not staged like many cancers; patients are placed in risk groups.) Ghobrial gave the Whelans something that would sustain them in those early, frightening days and in the years ahead—hope.
Managing His Cancer
Whelan benefits from having strong family support in facing his illness: Jan, his wife of 44 years, his three daughters and his twin granddaughters. (A third granddaughter is expected this winter.) He is also fortunate to live less than an hour from Dana-Farber, which offers a program for patients with Waldenström and opportunities to take part in clinical trials.

Patients with Waldenström who have no serious or troublesome symptoms often don’t need immediate treatment. Because he was already experiencing symptoms, however, Whelan started treatment soon after his diagnosis. “Although there are no FDA-approved treatments for Waldenström, we can use many drug therapies that are used for other blood cancers,” says Ghobrial. “So we have a lot of options to help delay the progression of the disease. Patient survival is getting better and better.”

Whelan underwent a blood-filtering process called plasmapheresis, which was intended to lower the level of IgM in his blood, and had weekly infusions of a biological therapy called Rituxan (rituximab). This synthetic antibody attaches to a protein on the surface of B lymphocytes and destroys the cells. Despite the treatments, however, Whelan’s IgM levels and percent of bone marrow involvement (an indicator of cancer cells in his bone marrow) showed no significant improvement. With conventional treatment unable to make a dent, Ghobrial discussed other options with Whelan and his family, including clinical trials.

Whelan did what comes naturally to him—extensive research. He scoured the web and connected with research advocacy groups. “I knew that I was not going to follow the historical path with traditional chemotherapies that often kill healthy cells as well as cancerous cells,” he says. “I wanted to try a different, less toxic approach through clinical trials.”

So far, Whelan has participated in four phase II clinical trials. In the first trial, he took a combination of Rituxan with Velcade (bortezomib) and, in subsequent trials, he took Afinitor (everolimus) and enzastaurin. He saw modest or no improvement from these trials. In the fourth trial, however, he experienced remarkable results with panobinostat, an oral anticancer drug that blocks enzymes needed for cancer cells to grow and divide.

Uncomfortable side effects led Whelan to stop taking the medication in November 2012. “I had headaches and high blood pressure when taking panobinostat,” he says. “The headaches were tolerable for a long time, but just kept getting worse, becoming a quality of life issue. Even though I was having a good response, I needed a rest.”

Despite stopping the medication, he saw his IgM levels continue to drop. As of early 2013, the level of cancer cells in his bone marrow was down from 80 percent at diagnosis to 20 percent.

It hasn’t been an easy road for Whelan, even though his condition has improved. In addition to the headaches and blood pressure problems caused by panobinostat, he suffered a host of other side effects during his treatments—heart palpitations, shaking, neuropathy, nausea, diarrhea, pneumonia and mouth sores. On two occasions during the clinical trials, he needed emergency care to treat severe side effects. Though the medications took a toll on his body, Whelan believes he chose a sensible path to meet his goals.

“The important thing is where I’ll be in the long term,” he says. “I think I chose the smarter alternative that will improve my outcome.”


Receive monthly updates, including information about web exclusives, events, resources, articles and highlights from new issues—direct to your email inbox. Be among the first to hear the latest news from Cancer Today! Click here to sign up!